

NO AGE

TUNISIA PHARMACEUTICAL MANUFACTURING ACTIVATION

Existing pharmaceutical assets | Equipment deployment |
Qualification | Production readiness

INDUSTRIAL PROJECT PRESENTATION

OCTOBER 2026

STERILE FILLING LINES
CONSISTENT QUALITY. EVERY VIAL. EVERY BATCH.

QUALITY CONTROL
TESTED. VERIFIED. TRACEABLE.

CLEANROOM PRODUCTION
CONTROLLED ENVIRONMENTS. SUPERIOR PURITY.

ADVANCED MANUFACTURING
SCALABLE. COMPLIANT. READY FOR A HEALTHIER WORLD.



GMP
FDA
EMA
ISO 13485
ICH

REGULATED
TRANSPARENT
TRUSTED
WORLDWIDE



An industrial project. Not only a healthcare concept.

From the identified factory equipment estate to a qualified manufacturing programme in Tunisia.



01 Industrial asset base

A documented manufacturing building, production equipment, laboratories and supporting utilities.

02 Equipment mobilisation

Confirm ownership, inventory and origin; move equipment to the designated Tunisian manufacturing site where required.

03 Validated startup

Install, qualify, test and release manufacturing capabilities against approved product requirements.

The acquired factory reference for manufacturing of nao products

PERLAMED S.A. – existing asset dossier and historical site profile becomes a member of GENESIS.



2017

COMPANY FORMATION

As stated in company presentation

Sbikha

INDUSTRIAL ZONE

Kairouan, Tunisia


5,767,340

SHARE CAPITAL (TND)

Historical dossier value

Actual equipment and facility assets

The following are photographs taken from the acquired-factory presentation, not generated concept images.



Industrial evidence supports equipment planning; operational condition, serial numbers, maintenance history and suitability still require inspection.

Production equipment | Unit operations

Documented solid-dose equipment gives the project a tangible industrial starting point.



Formulation and packaging machinery

Equipment photographs from the current asset presentation.



LOW-SPEED MIXER • SOURCE P. 12



BLISTER PACKAGING MACHINE • SOURCE P. 12

Controlled manufacturing environments

Personnel flow, clean production corridors and internal quality controls.



Quality-control laboratory infrastructure

Photographed laboratory areas and analytical equipment from the facility dossier.



LABORATORY ROOM • SOURCE P. 18



LAB EQUIPMENT • SOURCE P. 19



LAB STATION • SOURCE P. 20

Factory engineering | Utilities

A manufacturing startup is only as reliable as its air, water and process utilities.



AIR HANDLING



COMPRESSED AIR



CHILLED WATER



BOILER / PUMPS

Manufacturing footprint documented in the dossier

Historical area figures, to be reconfirmed against current site surveys and assets.

5,960 m²

COVERED AREA

880 m²

CLEANROOMS

1,400 m²

STORAGE SPACE



ADDITIONAL AREAS

400 m² analytical laboratories
680 m² technical utilities
2 × 1,000 m² technical floors

PHASE TWO

EQUIPMENT MOBILISATION IN TUNISIA

Inventory. Transfer. Install. Validate. Manufacture.

NOAGE / INDUSTRIAL DELIVERY PROGRAMME



One essential clarification: factory versus destination

The PERLAMED dossier locates its factory at Sbikha, Tunisia. The intended destination for transferred equipment is not named.

KNOWN FROM THE SOURCE

PERLAMED S.A.
Sbikha 2 Industrial Zone
Kairouan, Tunisia

TO BE CONFIRMED

Receiving site and ownership
Equipment origin and transport route
Assets included in transfer

The logistics plan below applies only to units that genuinely require relocation or redeployment.

Equipment-transfer work packages

A controlled chain of custody, not simply freight transport.

01 ASSET AUDIT

Serial numbers, condition, ownership and missing parts

02 ENGINEERING

Utilities, footprints, foundation and layout checks

03 DECOMMISSION

Safe disconnection, packing and preservation

04 TRANSPORT

Permits, insurance and specialist equipment handling

05 REASSEMBLY

Install, calibrate and connect to utilities

06 QUALIFICATION

IQ/OQ/PQ, trial lots and release controls

Tunisia manufacturing activation concept

Facility functional zones and hand-offs - conceptual arrangement, not a surveyed floor plan.

RECEIVING

Incoming inspection

QUARANTINE

Identity / status

MANUFACTURING

Controlled processing

PACKAGING

Primary / secondary

QC RELEASE

Batch disposition

WAREHOUSE

Finished goods

[Logical process flow →](#)

The critical equipment gap

A photographed oral-solid factory is not automatically a sterile peptide manufacturing facility.

DOCUMENTED ASSETS

- Tablet press
- Capsule filler
- Low-speed mixer
- Blister packaging
- Lab rooms and building utilities

ADDITIONAL CAPABILITY TO VALIDATE

- Peptide API synthesis or qualified sourcing
- Purification and analytical methods
- Sterile manufacturing if required
- Fill-finish and packaging qualification
- Product-specific stability and GMP controls

Product type, route of administration and regulatory classification determine which equipment is required.

Release gates: technical, quality and regulatory

Every gate needs evidence before a manufacturing claim is made.

A	Asset title & inventory	Machine IDs, asset records, condition
B	Site / engineering readiness	Civil, HVAC, water, compressed air
C	GMP gap closure	Quality systems, cleaning, personnel
D	Equipment qualification	Installation and performance records
E	Product validation	Methods, stability, batch reproducibility
F	Legal manufacturing authority	Approvals matching product and site



NOAGE

THE FUTURE CARE EXPERIENCE

A distinctive clinical and wellness environment supports the long-term brand story.

Visual concepts are not evidence of medical efficacy or approved treatment.

CONCEPT VISUALIZATION / NOT A REAL TREATMENT PHOTO

NoAge product and care vision

Separate future patient experience from the industrial programme and its validated product pathways.



CONCEPT IMAGE / ROBOTIC CARE ENVIRONMENT



CONCEPT IMAGE / IMMERSION-BASED WELLNESS DESIGN

Industrial partners and responsibilities

An execution model for equipment suppliers, pharmaceutical specialists and the Tunisian operating company.

ASSET / OWNER

Inventory and asset title
Vendor records and transport mandate
Supply of technical documents

INDUSTRIAL ENGINEER

Machine inspection and rigging
Utilities and plant installation
Factory commissioning and O&M

PHARMA / QUALITY

GMP gap assessment
Product registration strategy
Validated manufacture and QC release

Implementation leads, contractors and contractual delivery dates remain to be appointed.

Proposed startup roadmap

Illustrative sequence. Actual dates depend on site, equipment condition and regulatory scope.

0	DEFINE	Asset list / destination / product class
1	VERIFY	Technical inspection, due diligence, utilities
2	TRANSFER	Rigging, transport, delivery / customs if applicable
3	INSTALL	Mechanical / electrical reassembly and calibration
4	QUALIFY	IQ/OQ/PQ, laboratory / quality readiness
5	VALIDATE	Trial batches, release decision and regulated start

Executive decision package

What must be settled to convert the acquired assets into an actionable Tunisia manufacturing project.

FACILITY

Receiving-site identity and technical survey

ASSETS

Asset register, title and equipment inventory

PRODUCTS

Solid-dose, supplement or peptide product scope

FINANCE

Removal, transport, plant works and qualification budgets

NOAGE / TUNISIA

FROM EXISTING EQUIPMENT TO QUALIFIED PRODUCTION

Industrial assets are the foundation. Engineering evidence, validated processes and regulatory approval establish production readiness.

OCTOBER 2026 • PROFESSIONAL PARTNER DISCUSSION



Evidence register and visual provenance

Factory photographs and operational data are differentiated from concept illustrations.

PERLAMED S.A. — Presentation 2025	Factory overview, machines, cleanrooms, utilities and labs	Actual factory photographs from supplied file, pp. 3-22
NoAge Peptide Partner Presentation 2026	Peptide strategy, clinical pathway and brand direction	User-supplied presentation, 17 pages
NoAge healthcare image set	Futuristic clinics and patient environments	Concept illustrations only; not real factory or approved therapies
Project sponsor instructions	Acquired factory and delivery of equipment into Tunisia	Current transfer route, receiving plant and exact asset register not supplied

Equipment condition, acquisition chain, relocations, current licenses and production authorizations require independent verification.